NCAM1 and anti-neutrophil cytoplasmic antibody-associated vasculitis: Despite differences compared to healthy controls, CD3-(CD56 or 16)+ NK cell counts and percentages in AAV patients can presently not be recommended as disease activity marker in “real life” clinical practice.